Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To the Editor: Dr Freedman and colleagues1 report the occurrence of microangiopathic hemolytic
anemia in a case of cutaneous anthrax. This represents the second recent anthrax
case with this finding.2 Pathological reports
of inhalational anthrax cases from the Sverdlovsk epidemic3
suggest that vasculitis is the cause of the microangiopathic hemolytic anemia
observed in some cases of anthrax. Although pathological findings of disseminated
intravascular coagulation were not reported to be present in the Sverdlovsk
cases, laboratory findings compatible with the diagnosis occurred in some
patients. The vasculitis, as well as endothelial damage, were believed to
be responsible for the extensive hemorrhage that is a prominent feature in
disseminated anthrax infections. Thus, both microangiopathic hemolytic anemia
and hemorrhage may be consequences of vasculitis.
Friedlander AM. Diagnosis and Treatment of Cutaneous Anthrax. JAMA. 2002;288(1):43-44. doi:10.1001/jama.288.1.42